Current Report Filing (8-k)
September 28 2020 - 9:52AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): September 25, 2020
Adial
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in charter)
Delaware
(State
or other jurisdiction of incorporation)
001-38323
|
|
82-3074668
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
1180
Seminole Trail, Suite 495
Charlottesville,
Virginia 22901
(Address
of principal executive offices and zip code)
(434)
422-9800
(Registrant’s
telephone number including area code)
(Former
Name and Former Address)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbols
|
|
Name
of each exchange on which registered
|
Common
Stock
|
|
ADIL
|
|
NASDAQ
|
|
|
|
|
|
Warrants
|
|
ADILW
|
|
NASDAQ
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17
CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
September 25, 2020, Adial Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
issued a press release relating to the submission to the U.S. Food and Drug Administration (FDA) in support of the Company’s
position that AD04 should be considered eligible for an FDA expedited review program.
The
press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibit is filed with this Current Report on Form 8-K:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated: September
28, 2020
|
ADIAL
PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
William B. Stilley, III
|
|
Name:
|
William
B. Stilley
|
|
Title:
|
President
and Chief Executive Officer
|
2
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Sep 2023 to Sep 2024